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1. Introduction
Major depressive disorder (MDD) is a devastating disease in terms of human suffering, health
costs and economic burden to society. As described in the Diagnostic and Statistical Manual
of Mental Disorders, various symptoms can be observed in depressed patients including
disheartened mood, loss of interest or pleasure (anhedonia), feeling of guilt or worthlessness,
disturbed sleep or appetite, low energy, poor concentration and suicidal ideation. The
prevalence of MDD in the general population is 4.4% to 5% with an annual incidence of 2.4%
to 3.8% [1]. Regional variation in the 12-month prevalence of the major depressive episodes
was also noted, ranging from 2.2% in Japan to 10.45% in Brazil with similar averages of 5.5%
in developed and 5.9% in developing countries [2]. In the USA, 59% of MDD patients experi‐
ence severe degree of functional impairment, making depression the largest contributor to
work loss [3, 4]. Furthermore, MDD was strongly associated to self-perceived stress, childhood
adversity, working status and quality of life [5-7]. According to the estimation results reported
in the global burden of disease study (a study measuring disability-adjusted life-years, DALY),
MDD will have become the leading cause of disability in developed countries by the year 2030
[8], indicating that the situation is not likely to improve unless something changes. A major
contributor to this crisis is the lack of adequate medication to treat a large proportion of
patients. Indeed, 20% do not respond to antidepressants (ADs) recommended as “first-line”
drugs, 40% do so only partially, and among responders, there is a time lag of several weeks to
months before a meaningful clinical effect can be observed. Failure of clinical recovery with
the first AD treatment used and high risk of relapses are also common features. A common
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trait of all conventional ADs is that they have a similar mode of action, which is an enhancement
of synaptic transmission of the monoamines serotonin (5-HT) and/or norepinephrine (NE) [9].
In fact, development of AD medications was largely based on the monoaminergic theory of
depression that links the pathophysiology of this illness to a deficiency on cerebral 5-HT and/
or NE levels. Hence, first generation of ADs, monoamine oxidase inhibitors (MAOIs) and
tricyclic antidepressants (TCAs) inhibit the breakdown of 5-HT, NE and dopamine in presy‐
naptic neurons and block the presynaptic uptake of 5-HT and NE through high-affinity 5-HT
(SERT) or NE (NET) transporters, respectively. Although effective, the severe side effects and
toxicity of MAOIs and TCAs limited their usefulness. Later, drugs with more novel ap‐
proaches, including selective 5-HT reuptake inhibitors (SSRIs), NE reuptake inhibitors (NRIs)
and combined-action 5-HT/NE reuptake inhibitors (SNRIs) have been introduced, but as well
as the prior generation of ADs, they act through the modulation of monoamine transporters,
which may explain their suboptimal therapeutic efficacy. A number of emerging ADs that
target monoamine transmission attempt to act on existing targets in more synergic ways
(combining 5-HT reuptake inhibition with inhibition of autoreceptors) or to broaden the
spectrum of monoamine systems targeted (dopamine, melatonin) to either enhance efficacy
or speed response.
Nevertheless,  the complexity and heterogeneity of symptoms of MDD makes incompati‐
ble the association of a disease with a single pathophysiological disturbance. Hence, years
of research and efforts gave rise to a multitude of hypotheses trying to explain the different
facets of  this disorder.  For example,  studies have associated depression with abnormali‐
ties in the hypothalamus-pituitary-adrenal axis activity including elevated concentrations
of  the  corticotropin-releasing  hormone  in  the  cerebrospinal  fluid,  increased  volumes  of
adrenal gland and pituitary and an impairment of corticosteroid receptor signaling [10, 11].
Also, extensive studies reported circadian rhythms deregulations in depressed patients, as
well as an AD effect of drugs that are capable to resynchronize this biological rhythm (i.e.
agomelatine)  [12,  13].  Pro-inflammatory  cytokines  such  as  interleukin  (IL)-6  and  tumor
necrosis factors (TNF)-α were also implicated in depressive disorders [14, 15]. Other possible
mechanisms that have been suggested to be involved in the etiology and treatment of MDD
include deficit in the gamma-aminobutyric acid (GABA) transmission [16], dysfunction of
glutamatergic  system [17],  acetylcholine  imbalance  [18],  estrogens  [19,  20]  and so  many
others [21]. In spite of these hypotheses, one of the oldest, “the monoaminergic hypothe‐
sis of depression” which assumes that MDD is caused by an imbalance in serotoninergic,
norepinephrinergic and possibly dopaminergic functions, is still  driving clinical develop‐
ment of ADs since the empirical discovery of MAOIs and TCAs. Although these monoa‐
mines are undoubtedly involved, it is now recognized that, following AD administration,
changes in the levels of monoamines and subsequent adaptive processes,  in particular a
change in the sensitivity of some of monoamine receptors, are not sufficient on their own
to explain the mechanism of action of ADs. Indeed, it is difficult to correlate the time of
the delayed clinical onset of AD action (several weeks) with the increase in synaptic levels
of monoamines, as this change occurs already after the initial dose of the drug. In the last
decade,  investigations  focusing  on  mood  disturbances  have  been  extended  to  brain
neuroplasticity,  leading to  the  “neurogenic  and neurotrophic  hypothesis  of  depression”.
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This latter postulates that development of MDD is, at least partially, related to a reduced
neuroplasticity  and/or  depletion  of  neurotrophic  factors  which  can  lead  to  a  structural
deformity and functional impairment of the central nervous system.
The monoaminergic hypothesis of depression is still valid today, and intense research keeps
focusing on the 5-HT system, its implication in the pathophysiology of depression and in the
mode of action of ADs. Extensive data reported a number of cellular and molecular adaptive
changes of the 5-HT system both at pre- (i.e. autoreceptor desensitization) and postsynaptic
levels (i.e. stimulation of hippocampal neurogenesis and normalization of neurotrophins
levels) following long-term treatment with various classes of ADs [22-24]. These neuroadap‐
tations occurred with a time course consistent with the observation of a significant AD action.
Naturally, a number of questions has to be asked; how the 5-HT system reacts in case of
depression and after AD treatment? Which cellular and molecular actors are implicated in such
reaction? Which brain areas are prevalent in these responses? To address these questions and
others, the present chapter aims a better understanding of the biological basis of pharmaco‐
logical treatments of depression. Attention will be paid to the neuroadaptive consequences of
combination strategies (i.e. adjunction of antipsychotics) as well as promising targets on AD
development (5-HT7 receptor antagonism, 5-HT4 agonism).
2. Neuroadaptations according to the monoaminergic hypothesis
2.1. Chronic effects of the first generation of ADs on the 5-HT system
MAOIs and TCAs were the first ADs discovered and they have proven their efficacy for
treating MDD, particularly atypical depression, anergic bipolar depression and treatment-
resistant depression. However, they are not supported as first-line drugs in clinical use due to
life-threatening interactions with a variety of medications and common food as well as lethal
cardiac irregularities [25, 26]. Early preclinical studies showed that acute administration of
MAOIs (pargyline, tranylcypromine, phenelzine and iproniazid) and TCAs (clomipramine,
imipramine, amitriptyline and nortriptyline) suppresses the firing activity of 5-HT neurons in
the dorsal raphe nucleus (DRN) [27-29], which is reversed by an injection of the 5-HT1A
receptors antagonist, WAY-100635 [28, 30].
A prolonged administration of MAOIs induces a complete recovery of the firing activity
of DRN 5-HT neurons, an effect attributable to a desensitization of the somatodendritic 5-
HT1A  autoreceptors  since  the  reducing  effect  of  5-HT1A  receptors  agonists  is  completely
abolished (Figure 1) [31-33]. Accordingly, a reduction of the ability of 8-OH-DPAT to inhibit
forskolin-stimulated adenylate cyclase activity [34] and an increase of the ED50  for 8-OH-
DPAT induced lower lip retraction [35] were reported after chronic treatment with MAOIs
(MDL  72394,  clorgyline  or  tranylcypromine)  in  rats.  This  desensitization  of  5-HT1A
autoreceptors seems to occur at the level of receptor-G protein interactions rather than their
simple downregulation. In fact, an autoradiographic study showed that the 5-HT1A agonist-
stimulated [35S]-GTPγS binding is reduced in rats treated for 21 days with clorgyline [36].
Importantly, such chronic treatment with MAOIs was shown to increase the extracellular
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concentrations of 5-HT, an effect greater in raphe nuclei than in their projection areas [37].
A microdialysis study measuring the extracellular levels of 5-HT in the frontal cortex of
rats reported that chronic administration of the reversible MAOI MDL72394 significantly
increased 5-HT amounts,  without  having any effect  on the  ability  of  the  5-HT1A  and 5-
HT1B  agonist RU24969 to reduce these levels [38], suggesting that the sensitivity of these
autoreceptors are not affected by chronic treatment with MAOIs. This is supported by data
from  an  electrophysiological  study  demonstrating  that  long-term  administration  of
clorgyline increased the efficacy of the stimulation of the 5-HT pathway to suppress the
firing activity of CA3 pyramidal neurons of the dorsal hippocampus, whereas the enhanc‐
ing  effect  of  the  antagonist  of  the  terminal  5-HT  autoreceptors  methiothepin  remained
unchanged [39]. However, it is for high interest to note that long-term treatment with the
reversible  MAO-A inhibitor  befloxatone resulted in a  tonic  activation of  postsynaptic  5-
HT1A receptors located on the dorsal hippocampus CA3 pyramidal neurons since the highly
potent and selective antagonist, WAY-100635, markedly increased the firing activity of these
neurons (Figure  2]  [40].  It  is  also  noteworthy that  MAO-A knock-out  mice  exhibit  high
extracellular amounts of 5-HT and an overall decrease of 5-HT1A receptors density, including
raphe autoreceptors as well  as hippocampus and spinal cord postsynaptic receptors [41,
42].  In  summary,  chronic  treatment  with  MAOIs  does  desensitize  inhibitory  5-HT1A
autoreceptors, keep sensitivity of terminal 5-HT autoreceptors unaltered and enhance the
tonic activation of  postsynaptic  5-HT1A  receptors.  Similarly to MAOIs,  chronic treatment
with TCAs (imipramine, iprindole, desipramine and femoxetine) did not change the mean
firing  rate  of  the  DRN  5-HT  neurons  in  comparison  to  controls  [31].  However,  the
responsiveness  to  intravenous  injection  of  the  5-HT agonist  LSD or  the  effectiveness  of
microiontophoretic application of 5-HT and LSD were not altered by such treatment [31],
suggesting that the sensitivity of the 5-HT autoreceptors is  not modified. The 5-HT1A/G-
protein  coupling  is  usually  assessed  by  measuring  [35S]-GTPγS  binding  induced  by  5-
HT1A  receptor  activation  [43].  It  was  reported  that  chronic  treatment  with  the  TCA
amitriptyline did not alter the 5-HT1A agonist-stimulated [35S]-GTPγS binding in dorsal and
median  raphe  nuclei  [44,  45],  further  confirming  an  absence  of  desensitization  of  the
somatodendritic  5-HT1A  autoreceptor  following  chronic  TCAs.  In  contrast,  the  same
treatments have different effects on postsynaptic levels.  Indeed, long-term application of
imipramine  increased  the  responsiveness  of  postsynaptic  CA3  hippocampus  pyramidal
neurons  to  the  microiontophoretic  application  of  5-HT  or  8-OH-DPAT  [46].  In  accord‐
ance, Rossi et al. [45] showed that chronic administration of amitriptyline increased the 5-
HT1A  receptor-stimulated [35S]-GTPγS binding in the hippocampus,  without affecting the
binding of [3H]8-OH-DPAT (indicating the number of 5-HT1A receptors in the coupled high-
affinity agonist state).  These authors suggest that,  in absence of an increase in the bind‐
ing of [3H]8-OH-DPAT, the increased capacity of 5-HT1A  receptors to activate G proteins
in CA1 and dentate gyrus of the hippocampus may be due to regulatory changes at the
level of the G protein, e.g. phosphorylation [45]. In summary, chronic TCA treatment does
not desensitize inhibitory 5-HT1A  autoreceptors and enhance the sensitivity of postsynap‐
tic 5-HT1A receptors in the hippocampus.
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Figure 1. Representation of the effects of the serotoninergic antidepressants on 5-HT neurotransmission. Monoamine
oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs) act on the 5-HT system, respectively, by
inhibiting the 5-HT degradation and by blocking the 5-HT transporter (SERT). Their administration induces the raise of
extracellular levels of 5-HT which activate 5-HT receptors. In the raphe nuclei, the somatodendritic 5-HT1A autorecep‐
tors negatively control the firing activity of the 5-HT neurons, while the 5-HT1B/1C autoreceptors control the 5-HT re‐
lease. Long-term administration of both classes of antidepressants desensitize 5-HT1A autoreceptors. Modified from
Faure et al. [22].
Basal 
condition 
Antidepressant 
treatment  
Pyramidal neuron of hippocampal CA3 area  
WAY-100635 
5-HT1A 
Following 5-HT1A receptor antagonist WAY-100635 
Figure 2. Representation of the effect of antidepressant treatments on hippocampal neurons. The raise of extracellu‐
lar 5-HT levels decreases the firing activity of hippocampus CA3 pyramidal neuron and this is mediated by postsynaptic
5-HT1A receptors. In control animals, no or low firing activity increase is observed after administration of the antagonist
WAY-100635. However, in antidepressant-treated animals, WAY-100635 disinhibits pyramidal cells, suggesting that
antidepressants increase 5-HT tone in the hippocampus. Modified from Blier and de Montigny [201].
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2.2. Chronic effects of the SSRIs on the 5-HT system
SSRIs represent the first-line ADs in clinical use nowadays, mainly due to their relatively lower
burden of adverse effects and safety in overdose. SSRIs include fluoxetine, fluvoxamine,
paroxetine, sertraline, citalopram, escitalopram and more recently vilazodone [47, 48]. These
drugs are believed to exert their effects by blocking SERT, which induces an increase of 5-HT
synaptic levels. In turn, the chronic enhancement of 5-HT bioavailability produces numerous
neuroadaptive changes leading to an enhancement of the 5-HT neurotransmission (Figure 1)
[22, 40, 49]. In particular, it was widely reported that acute administration of SSRIs inhibits the
firing activity of the 5-HT neurons in DRN, resulting from an enhancement of somatodendritic
5-HT release which activates the 5-HT1A autoreceptors [50-55]. However, immunoelectron
microscopy studies using specific antibodies showed a significant decrease of the 5-HT1A
immunogold labeling of the plasma membrane of the DRN dendrites and an increase in their
cytoplasmic labeling after a single injection of the SSRI fluoxetine in animals, indicating an
internalization of these autoreceptors under acute conditions [56, 57]. Importantly, a very
recent double-blind positron emission tomography study investigated the binding of the 5-
HT1A radioligand [18F]MPPF in human volunteers after taking a single tablet of fluoxetine or
placebo. This study clearly demonstrated that in DRN, and nowhere else in the brain, a
significant decrease in [18F]MPPF binding potential between fluoxetine and placebo [58]. In
animals, this autoreceptor internalization seems to be very transient since a microdialysis
study reported that administration of a 5-HT1A receptor agonist a few hours after single
injection of fluoxetine reverses the SSRI-induced increase in the 5-HT levels [59]. Short-term
treatment with SSRIs also reduced the firing activity of the DRN 5-HT neurons [50]. Only
chronic (2 to 3 weeks) treatments with these drugs completely recover the 5-HT firing activity,
and this is accompanied with a desensitization of the somatodendritic 5-HT1A autoreceptors
[50, 51, 60, 61]. Interestingly, when rats chronically treated with fluoxetine were challenged
with a single dose of 8-OH-DPAT, there was no internalization of the 5-HT1A autoreceptors in
keeping with their desensitized form [62]. In fact, after such treatment, neither the density of
the 5-HT1A autoreceptors on the plasma membrane of DRN neurons nor the [18F]MPPF binding
were changed [56, 58, 62, 63]. One explanation is that, after repeated internalization and
retargeting, functional 5-HT1A autoreceptors are replaced by receptors uncoupled from their
G proteins (inactivated form of the receptor) on the plasma membrane of DRN 5-HT neurons
[62]. However, controversial results have been reported about the effects of chronic SSRI
treatment on the functional status of the 5-HT1A autoreceptors. An attenuation of 8-OH-DPAT-
mediated [35S]-GTPγS stimulation has been consistently observed in the DRN by certain
groups after chronic fluoxetine [36, 44, 49, 64, 65], while others reported no change in this
parameter after chronic sertraline or citalopram [63, 66]. These findings raised the possibility
that SSRIs may not be a homogenous class of AD drugs with regard to the mechanism by which
the function of somatodendritic 5-HT1A autoreceptors is regulated. Thus, at least in the case of
fluoxetine, acute and chronic treatments seem to induce two distinct types of 5-HT1A autore‐
ceptor desensitization: one rapid and reversible (associated with the internalization of the
functional pool of membrane-bound receptors), the other being progressive and long-lasting,
no longer accompanied with receptor sequestration, but which probably resulted from the
reiteration of this process throughout the course of chronic fluoxetine treatment [58]. Another
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picture can be drawn for the postsynaptic 5-HT1A heteroreceptors. In fact, neither acute nor
chronic treatment with SSRIs induced a change in the subcellular distribution of the 5-HT1A
receptors in dendrites or in the in vivo binding of the 5-HT1A radioligand [18F]MPPF in
projection areas, particularly hippocampus and frontal cortex [56, 62, 63]. Such differences
between 5-HT1A receptors in DRN and projection areas were explained by a differential
coupling, the autoreceptors being coupled to Gαi3 while heteroreceptors are coupled to Gαo
protein [67]. However, agonist-induced [35S]-GTPγS binding data showed an increase [36, 63,
64] or no change [44, 49, 68] after long-term SSRI treatment, further adding complexity to the
whole picture. Importantly, long-term application of SSRIs produced an increase in tonic
activation of pyramidal neurons, indicated by the disinhibition of firing rate in response to the
antagonist WAY-100635 (Figure 2) [40, 51]. This further supports the increase of the efficacy
of the 5-HT neurotransmission seen in vivo (enhancing the effectiveness of the stimulation of
the 5-HT pathway to suppress the firing activity of CA3 pyramidal neurons) and in vitro
(increasing the electrically-evoked release of tritiated 5-HT from preloaded hippocampal
slices) [46, 69]. More recent studies noted a decrease in the density of the 5-HT4 receptor binding
in the CA1 field of hippocampus of rats as well as in several areas of the striatum after a 21-
day treatment with the SSRI fluoxetine [70]. The activity of these postsynaptic receptors in the
hippocampus, measured as the excitatory action of the 5-HT4 agonist zacopride in pyramidal
cells of CA1 evoked by Schaffer collateral stimulation, was attenuated also after such chronic
treatment [70]. This suggests a net decrease in the signalisation pathway of 5-HT4 receptors
after chronic SSRI treatment. In addition, desensitization of the 5-HT7 receptors [71] and
downregulation in the 5-HT7 binding site in the hypothalamus [72] were reported following
chronic treatment with fluoxetine.
Another interesting consequence of chronic, but not acute, treatment with SSRIs is a reduction
of the surface expression of SERT. In fact, electron microscopy studies reported that long-term
administration of fluoxetine induced an internalization of SERT in both cell bodies and axon
terminals of 5-HT neurons [58]. Moreover, the total amounts of SERT immunoreactivity is also
reduced, suggesting that, rather than a simple internalization, a long-term degradation of this
protein happened in the course of the treatment [58].
2.3. Chronic effects of new antidepressant strategies
The suboptimal efficacy and the delayed onset of action of different classes of ADs raises the
necessity to find new strategies to treat depression, especially treatment-resistant depression
and depressive episodes associated with bipolar disorders. For example, a number of second-
generation antipsychotics have been investigated and approved for use as augmentation
agents in combination with currently approved first-line ADs such as adjunctive aripiprazole,
olanzapine or quetiapine to standard doses of SSRIs [73-75]. The effect of such combination on
the 5-HT system is yet not well described in the literature, and only very recent preclinical
studies began to investigate their mechanisms of action. For example, Chernoloz et al. [76]
showed in rats that long-term administration (14 days) of quetiapine alone or in combination
with the SSRI escitalopram led to significant inhibition of the spontaneous firing activity of the
DRN 5-HT neurons, while escitalopram alone (as previously described for SSRIs) induced a
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recovery of this neuronal activity at this time point. Co-administration of quetiapine and
escitalopram for 14 days produced an increase in tonic activation of postsynaptic 5-HT1A
receptors located on the dorsal hippocampus CA3 pyramidal neurons, but in the same range
as that obtained with chronic escitalopram alone [76]. The enhancement in 5-HT transmission
produced by this combination was attributable to the attenuated inhibitory function of α2-
adrenergic receptors on 5-HT terminals and possibly to direct 5-HT1A receptor agonism by
quetiapine [76]. Similarly, risperidone co-administered with escitalopram for 14 days was
shown to prevent the restoration of the 5-HT neuronal firing rate, obtained with the SSRI alone
[77]. Therefore, it might be suggested that risperidone co-administrated with the SSRIs
increases 5-HT neurotransmission by indirect action on the 5-HT system. Indeed, Marcus et
al. [78] reported that adjunctive low-dose of risperidone to escitalopram significantly enhanced
both dopamine outflow and NMDA receptor-mediated transmission in the medial prefrontal
cortex (PFC) of rats. Taken together, these results pointed out the possibility that, rather than
a direct action on the 5-HT system, combining an SSRI and an antipsychotic of second-
generation implicate multiple neurotransmitter systems to exert their beneficial effects.
Among novel targets to develop more efficacious and fast-acting ADs, 5-HT4  and 5-HT7
receptors  are  promising candidates  [71,  79].  For  example,  brain  regional  changes  in  the
binding of the 5-HT4 receptors were found in murine models of depression-related states
including  olfactory  bulbectomy  model,  glucocorticoid  receptor  heterozygous  mice  and
Flinders sensitive line depression model [80, 81]. Lucas et al. [79] showed in rats that a 3-
day treatment with the 5-HT4 receptor agonist RS67333 modifies several rat brain parame‐
ters considered as key markers of AD action, which are changed only after 2 to 3 weeks
with classical ADs. These changes include desensitization of the 5-HT1A autoreceptors and
increased tonus on hippocampal postsynaptic 5-HT1A receptors [79]. Accordingly, subchron‐
ic  (3  days)  administration  of  RS67333,  but  not  acute,  increased  basal  5-HT  levels  and
decreased its metabolite levels 5-HIAA in the rat ventral hippocampus [82]. Furthermore,
a 3-day co-administration of the SSRI citalopram and a 5-HT4 receptor agonist, RS67333 or
prucalopride, resulted in an increase of DRN 5-HT neuron mean firing activity, display‐
ing a similar, or even slightly superior, firing amplitude obtained with each agonist alone
[83]. At the postsynaptic level, this translated into the manifestation of a tonus on hippocam‐
pal postsynaptic 5-HT1A receptors, which was two to three times stronger when the 5-HT4
receptor agonist was combined with citalopram [83]. This suggests an important increase
on the 5-HT neurotransmission following adjunction of an SSRI to a 5-HT4 receptor agonist,
clearly indicating a rapid AD-like potential of these agonists.
Moreover,  antipsychotics (lurasidone,  amisulpride),  as well  as a novel AD-like multimo‐
dal 5-HT agent (Lu-AA21004),  have been proved to be potent 5-HT7  antagonists [84-88].
Furthermore, genetic deletion of this receptor confers to mice AD-like behaviors including
decreased immobility in the forced swim and tail suspension tests as well as shorter and
less frequent episodes of rapid eye movement sleep [89], indicating that antagonists might
have therapeutic value as ADs. In this context, we showed that a 1-week treatment with
the selective 5-HT7  receptor antagonist,  SB-269970,  did not  alter  5-HT firing activity but
desensitized somatodendritic  5-HT1A  autoreceptors  and enhanced the  tonic  activation of
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postsynaptic 5-HT1A receptors in the hippocampus [71]. Taken together, these findings show
that new AD strategies targeting 5-HT receptor manipulation resulted in similar adaptive
changes of the 5-HT system than those produced by classical ADs, except that they took
place faster in both pre- and postsynaptic levels.
In summary, a change of 5-HT receptor sensitivity that occurs only after chronic treatment
seems to be a common mechanism of AD action, which takes place depending on the delay
onset of action of each 5-HT AD. This represents the major argument supporting the 5-HT
hypothesis of depression. However, it became obvious that depression involves further
modifications besides those at the 5-HT system. Several studies emerged to assess new
pharmacological models that may help to better understand the mechanisms and pathophy‐
siological changes leading to a depressive behaviour.
3. Neurogenic and neurotrophic adaptations induced by 5-HT
antidepressants
Recent studies indicate that an impairment of cellular and synaptic plasticity in specific areas
of the brain, especially the hippocampus and PFC, may be a core factor in the pathophysiology
of depression. The abnormal neuronal plasticity including neurogenesis, axon branching,
dendritogenesis and synaptogenesis was suggested to be related to alterations in the level of
neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) which plays a
central role in the adaptation of neural networks. Numerous studies reported that AD
treatments may act by normalizing neurotrophic levels in the brain and enhancing neurogen‐
esis and synaptogenesis, leading to a gain of function in neuronal networks altered by
depressive states. In the following paragraphs, we enumerate the chronic effects of the
previously cited AD strategies on the cellular and synaptic plasticity, as well as neurotrophin
expression. A critical view of the role of each parameter on the etiology of depression and AD
action is also described.
3.1. Neurogenesis
The first  evidence of  newly generated neurons in the adult  central  nervous system was
reported in 1965 when Altman and Das [90] used 3H-thymidine to label proliferating cells
in  the  rat  dentate  gyrus  (DG)  of  the  hippocampus.  Subsequent  studies  confirmed  the
existence  of  this  hippocampal  neurogenesis  in  adulthood  in  several  species  including
humans [91, 92], using the new tool bromodeoxyuridine (BrdU), a thymidine analog that
labels dividing cells in S-phase [93]. In the hippocampus, progenitor cells are located in the
subgranular zone (SGZ) where they divide and a subset of the new cells survive, migrate
into granule cell layer and differentiates into neurons. An excellent review of Hanson et al.
[94] described the timeline of cell division and maturation as well as markers of cells from
different  stages  of  neurogenesis  in  the  SGZ.  The  subventricular  zone  (SVZ)  was  also
identified as a highly neurogenic area of the adult brain [95], although other regions retain
the potential to generate new neurons [96-98].
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The  hippocampal  neurogenesis  was  shown  to  be  implicated  in  the  pathophysiology  of
depression (Table 1). Clinical studies showed that patients suffering from MDD had lower
hippocampal  volume  than  healthy  subjects  [99,  100],  that  may  be  linked  to  increased
neuronal atrophy. Only patients who remitted after 8 weeks of AD treatment present larger
hippocampal volume in comparison to subjects who did not remit [101]. A more evident
correlation came firstly from the preclinical study of Santarelli  et al.  [102].  In this study,
mice treated 28 days with the SSRI fluoxetine exhibited an increase in the number of BrdU-
positive cells in the SGZ of DG with a concomitant decrease in the latency to feed in the
novelty suppressed-feeding (NSF) paradigm. However, ablation of cell proliferation in the
SGZ, but not the SVZ, following X-ray treatment suppressed behavioral responses to chronic
fluoxetine [102]. The requirement of hippocampal neurogenesis for therapeutic efficacy of
ADs was subsequently confirmed in non-human primates [103]. Consistent with the time
course of their therapeutic action, only chronic treatment regimen with MAOIs [104, 105],
TCAs [106, 107], SSRIs [61, 102, 105, 108], putative fast-acting AD drugs including 5-HT4
agonists [79] and 5-HT7 antagonists [71] and finally adjunctive strategies (olanzapine plus
fluoxetine) [108] increased the cell proliferation in the SGZ of the hippocampus at compa‐
rable  extent.  This  indicates  that  upregulation  of  hippocampal  neurogenesis  may  be  a
common denominator of the mechanism of action of ADs. Although the function of these
newly generated cells in the adult brain is still unclear, it has been suggested that young
granule cells constitute a distinct population exhibiting a greater degree of plasticity than
mature neurons. In particular, they display a reduced threshold to induction of long-term
potentiation (LTP)  [109],  and can be  tonically  activated by ambient  GABA before  being
sequentially  innervated  by  GABA-  and  glutamate-mediated  synaptic  inputs,  leading  to
marked defects in their synapse formation and dendritic development in vivo [110].
Given the emergence of new data, the initial research cited above suggesting a model of
hippocampal degeneration as basis of depression and reversal by ADs through neurogenesis
seems to be uncertain. In fact, as chronic ADs, mood stabilizers (lithium) and atypical anti‐
psychotics induce hippocampal cell proliferation [108, 111-113], but whether these drugs can
be used as monotherapy in depression is an area of debate and clinical data failed to support
it. It is also noteworthy that, even in the famous study of Santarelli et al. [102], X-ray of
hippocampus suppressing neurogenesis in non-treated rats failed to induce a depressive-like
behavior. Accordingly, cyclin D2 (a protein involved in the cell cycle regulation) knock-out
mice, specifically lacking adult brain neurogenesis, showed normal anxiety levels in the open-
field and elevated plus maze [114]. In contrast, increasing hippocampal neurogenesis in mice
was not reported to produce anxiolytic or AD-like behavioral effects [115]. These latter reports
add complexity to the understanding of the role of altered neurogenesis in the pathology of
depression. That is why, some neuroscientists postulate that, beyond a simple increase of
hippocampal neurogenesis in response to ADs, insertion of the newly generated neurons (even
a small number) in functional neural networks especially through synaptogenesis, may be
more relevant for the explanation of their mechanism of action.
In this context, an elegant theory in which neurogenesis is seen as an epiphenomenon of a
more widespread alteration in dendritic length and spine number was already proposed [116].
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According to this theory, exposure to chronic stress and stressful life events increases excito‐
toxic glutamatergic neurotransmission in multiple brain areas. To protect neurons from
consequent apoptosis, dendrites retract and spine number decreases thus limiting the number
of exposed glutamate receptors.
3.2. Synaptic plasticity and synaptogenesis
The regulation of synapse formation or synaptogenesis is a subcellular neuronal alteration that
contributes to synaptic plasticity [117, 118], which defines the ability to integrate informations
from different neuronal inputs and make the appropriate adaptive responses. An increase in
functional synaptogenesis is typically accompanied by an increase in the number of dendritic
spines, the physical site of synaptic connections [118, 119]. In recent years, it has become clear
that spines are dynamic structures that undergo rapid remodeling important for synapse
formation, function and plasticity [120, 121]. In the adulthood, spines continue to remodel in
response to a variety of physiological stimuli. For example, synaptic activity that induces LTP,
a long-lasting enhancement of synaptic strength, promotes spine enlargement and new spine
formation [122], whereas activity that induces long-term depression (LTD), a persistent
weakening of synaptic strength, causes spine shrinkage or retraction [123]. The potential role
of spines and dendrites in MDD (Table 1] is supported by preclinical studies demonstrating
that exposure to chronic stress negatively influence dendritic spine density and morphology
in brain areas such as DG, CA1 and CA3 subfields of the hippocampus and PFC [124-126]. This
includes a decrease in spine density, dendritic length and branch number [127, 128]. These
effects could contribute to the reduction in volume of PFC and hippocampus determined by
imaging the brains of depressed patients [100, 101, 129]. In accordance, a recent study revealed
lower expression of synaptic function-related genes in the dorsolateral PFC of MDD subjects
and a corresponding lower number of synapses [130].
As for neurogenesis, ADs regulate these different forms of synaptic plasticity. Synaptic
communication is altered by chronic stress which impairs LTP and facilitates LTD induction
in the CA1 of the hippocampus [131-133]. It has been reported that repeated application of the
SSRI fluvoxamine (21 days) increased the extent of LTP induction in the CA1 region of rats
that experienced chronic mild stress [131]. Using rats neonatally-exposed to clomipramine as
an animal model of depression, Bhagya et al. [134] found that these animals displayed a
decreased LTP in the hippocampal CA1 and a 14-day treatment with the SSRI escitalopram
restored this LTP. Similarly, retrieval of LTP in the CA1 field of hippocampus was obtained
in stressed animals after repeated application of other classes of ADs including the SNRI
milnacipran and electroconvulsive stimulation (ECS) [132, 135]. In contrast, other groups
described an impairment of LTP after chronic SSRI fluoxetine, TCA imipramine, SNRI
venlafaxine or ECS, but in non-stressed animals [136-138], indicating a stress-dependent action
of the ADs on hippocampal LTP. In the same way, chronic fluoxetine was reported to increase
dendritic spine density and arborization of granule cells in the mouse hippocampus [139,
140]. Daily administration of fluoxetine to ovariectomized rats for 5 days was shown to induce
a robust increase in pyramidal cell dendritic spine synapse density in the hippocampal CA1
field, with similar changes appearing in CA3 after 2 weeks of treatment [141]. This rapid
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synaptic remodelling might represent an early step in the fluoxetine-induced cascade of
responses that spread across the entire hippocampal circuitry, leading to the restoration of
normal function in the hippocampus [141]. In accordance, a recent study using ovariectomized
hamsters exposed to diminished light at night displayed depressive-like behaviors and
reduced hippocampal CA1 dendritic spine density, but a 2-week treatment with citalopram
rescued this behavior and moderately improved the spine density in the CA1 but not fully
restored it [142]. Also, chronic treatment with the TCA amitriptyline reversed the bulbectomy-
induced reduction in dendritic spine density in CA1, CA3 and dentate gyrus of hippocampus
[143]. It has to be noted that single injection of the 5-HT4 receptor partial agonist SL65.0155
does not promote spine growth in the naive mouse hippocampus [144], and the 5-HT7 receptor
agonist AS-19 increased neurite length and number in primary embryonic hippocampal
neurons [145], still the characterization of the in vivo effects of their chronic manipulation is
missing. It is obvious that the effects on synaptic plasticity of chronic treatment with different
AD strategies will be an important area of further research.
Significant evidence suggests that ADs regulate synaptic plasticity and reorganization through
the modulation of cell adhesion protein and synaptic function/structure related genes. In
particular, the neural cell adhesion molecule NCAM is necessary for activity-dependent LTP
in the hippocampus [146]. Its highly sialylated isoform PSA-NCAM promotes plasticity
through the negatively charged PSA, postulated to be a spacer that reduces adhesion forces
between cells allowing their dynamic changes [147]. It was reported that chronic treatment
with the selective MAO-B inhibitor deprenyl, the TCA imipramine or the SSRI fluoxetine
increased the expression of PSA-NCAM in the hippocampus and medial PFC [148-151].
Interestingly, chronic exposure to second-generation antispychotics olanzapine or risperidone
enhances PSA-NCAM expression in the PFC, but not in the hippocampus, suggesting that
modulation of cell adhesion protein in the hippocampus may be specific to the mechanism of
action of ADs [152, 153]. Moreover, an increased expression of synaptophysin, a glycoprotein
localized in presynaptic vesicle membranes required for docking and fusion of neurotrans‐
mitter-containing synaptic vesicles as well as endocytosis [154], was observed in hippocampus
and/or cerebral cortex of rats chronically treated with the MAOI tranylcypromine, the TCA
amitriptyline or the SSRI fluoxetine [148, 155, 156]. Also, Arc (Activity-regulated, cytoskeletal-
associated protein), a highly expressed protein in dendrites and postsynaptic densities [157]
is implicated in LTP and spine size and type [158-160]. Repeated administration (14 days) of
the SSRI paroxetine, the TCA desipramine or the MAOI tranylcypromine increased Arc mRNA
and the number of Arc-immunoreactive cells in frontal and parietal cortex as well as in the
CA1 region of the hippocampus, while acute injection had no effect [161].
How do ADs exert their effect on synaptic plasticity is a matter of discussion. Several putative
mechanisms have been proposed in this context. However, the observation that antidepres‐
sants increased anti-apoptotic factors and the synthesis of neurotrophic factors raises the
possibility that these drugs act via a mechanism of neuroprotection rather than a neuroregen‐
eration [23]. Particular attention was given to neurotrophins such as brain-derived neurotro‐
phic factor (BDNF).
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3.3. Neurotrophins modulation by 5-HT antidepressants
Neurotrophins are growth factors with crucial roles in the formation and plasticity of neuronal
networks [162], and BDNF is the most studied in this context. The dystrophic action of stress
was reported in animal models of depression (Table 1). Animals exposed to chronic stress such
as chronic mild stress or social deprivation displayed a decrease in the protein levels of BDNF
and an increase of its receptor tyrosine-kinase TrkB in several brain regions including hippo‐
campus (DG, CA1 and CA3), frontal cortex and midbrain [163-168]. BDNF-deficient mice or
with specific knockdown of BDNF in the DG also displayed depressive-like behaviors [169,
170]. Accordingly, drug-free MDD patients showed lower serum or plasma BDNF levels in
comparison to healthy subjects [171-174]. Moreover, human BDNF gene polymorphism
Val66Met was suggested to be related to the pathophysiology of MDD and affect clinical
response to AD treatment [175-177].
Studies Stress type Neuroplasticity consequence References
Preclinical
Repeated restraint stress
paradigm in rats
Reduction on the number and length of apical
dendritic branches in mPFC
[127]
[126]
Atrophy of apical dendrites of CA3 pyramidal neurons [201]
LTP suppression in DG and CA3 in a site-specific manner [202]
Chronic unpredictable stress
paradigm in rats
Dendritic atrophy in CA3 region
Atrophy in granule and CA1 pyramidal neurons
[125]
LTP impairment in CA1 area and decrease of
synaptophysin density in CA3 region
[131]
Decrease in BDNF mRNA level in hippocampus and
cerebral cortex
[203,204]
Chronic corticosterone
administration in rats
Atrophy in granule and CA1 pyramidal neurons
Dendritic atrophy in CA3 area
[125]
Retraction of apical dendrites in mPFC [205]
Decrease in BDNF mRNA level in hippocampus and
cerebral cortex
[204]
Chronic sleep deprivation in
rats
Decrease in hippocampal volume [207]
Suppression of cell proliferation in the hippocampus [208]
Impairment of LTP in the CA1 region [209]
Clinical
Unipolar depression Lower hippocampal volume [99, 210]
Volume reduction in orbitofrontal cortex, frontal
cortex, hippocampus, striatum, and cingulate cortex
[128]
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Studies Stress type Neuroplasticity consequence References
Recurrent MDD Lower hippocampal volume [211, 212]
Reduced volume in dorsolateral prefrontal cortex [213]
Lower plasma BDNF [172]
First-episode depression Lower hippocampal volume [214, 215]
Smaller left hippocampal volume only in males [216]
Lower plasma BDNF [172]
Late-life depression Reduction in hippocampal volume [217, 218]
Specific reduction in left hippocampus [219]
Volume reduction in orbitofrontal cortex, putamen
and thalamus
[217]
Lower plasma BDNF [220]
Familial recurrent MDD Smaller volume of the right hippocampus [221, 222]
Cumulative adversity
(recurrent stressful life
events)
Smaller volume in medial prefrontal cortex, insular
cortex and subgenual anterior cingulate regions)
[223]
Table 1. Effects of chronic stress and depression on different neuroplasticity actors in the brain. mPFC: median
prefrontal cortex. DG: dentate gyrus. LTP: long-term potentiation. BDNF: Brain-derived neurotrophic factor. MDD:
major depressive disorder.
Intracortical infusion of BDNF in the adult rat was shown to produce a robust sprouting of 5-
HT nerve terminals and accelerated the regrowth of 5-HT axons in basal conditions or
following their destruction [178, 179]. AD treatments could oppose or reverse the actions of
stress on the 5-HT system via a positive action on cerebral BDNF. Indeed, several studies
showed that long-term AD treatments including SSRIs (fluoxetine) and MAOIs (tranylcypro‐
mine, phenelzine) increase BDNF levels in the brain [168, 180-182], although a time-dependent
modulation seems to occur. Indeed, De Foubert et al. [182] demonstrated in rat hippocampus
that a 4-day administration of the SSRI fluoxetine decreased BDNF mRNA levels, a 7-day
treatment had no effect, but a 14-day treatment increased it. One explanation of this biphasic
change in BDNF gene expression could be a differential transcript regulation, since the rat
BDNF gene expresses four mRNA isoforms which can be modulated by different signaling
cascades. In fact, a recent study demonstrated that acute injection of fluoxetine or tranylcy‐
promine decreased total BDNF mRNA (exon V) as well as exon IV mRNA with no significant
changes on exon I or III mRNAs [183]. In contrast, chronic administration of these two drugs
enhanced expression of exon V and exon I mRNAs with no changes for exon III or IV [183]. It
is of high interest to note that ADs, besides regulating BDNF levels in naive animals, normalize
it under stress conditions. Hence, chronic treatment with fluoxetine increased the BDNF
protein till control levels in the hippocampus of rats experiencing chronic mild stress [184],
indicating that AD treatment can oppose the dystrophic actions of stress. Accordingly, clinical
studies reported that untreated depressed patients showed a decrease of serum or platelet
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BDNF levels before treatment, and a normalization of this parameter following several weeks
of SSRI (escitalopram or paroxetine) administration accompanied with an improvement in
depressive symptoms [185, 186]. Unfortunately, very few studies were conducted in this field
using novel ADs targeting the 5-HT system. For example, subchronic administration (3
injections in 24h) of the 5-HT4 receptor partial agonist SL65.0155, but not citalopram or
clomipramine, was reported to enhance hippocampal BDNF protein levels in rats, further
supporting a fast-acting AD profile of 5-HT4 receptor agonists [187]. Also, Agostinho et al.
[188] reported that combinatory treatment for 28 days with olanzapine and fluoxetine had no
effect on BDNF protein levels but enhanced specifically in the PFC the protein levels of NT-3,
a neurotrophin implicated in the pathophysiology of MDD [189]. However, these authors
reported also that 28 days of fluoxetine administration did not increase BDNF proteins levels
neither in the hippocampus nor in the PFC, even at high doses [188], raising some concern
about this study. Obviously, more investigations are needed to characterize the exact effects
on BDNF of these new treatment strategies.
4. Conclusion
The study of MDD is a real challenge for those who want to reveal the pathophysiological basis
of this disease. The monoaminergic and neurotrophic/neurogenic hypotheses cited in this
review give only a partial explanation of this basis. In the former, the function of a number of
5-HT receptors is still not yet elucidated and growing data implicate each receptor in a different
way in the AD mechanism of action. In the latter, the role of new-added neurons in the
hippocampus is still under investigation, although their integration in functional networks
may confer additional plasticity to rescue stress effects. These hypotheses can be considered
complementary as the activation of monoamine receptors may modulate the expression of
intracellular proteins and neurotrophic factors, permitting the re-organization of complex
neuronal networks involved in depression. Hence, ADs, particularly those targeting the 5-HT
system, were shown to induce changes at the level of 5-HT autoreceptors localized in the raphe
nuclei as well as the activation of neurotrophic factors expression and induction of cellular
proliferation within projecting areas such as the hippocampus. Yet, combining these two
hypotheses is not sufficient to fully explain the pathophysiology of depression, since conven‐
tional ADs were shown to modulate each factor (5-HT sensitivity, hippocampal cell prolifer‐
ation, neurotrophic expression), but still displaying moderate efficacy to alleviate depression
symptoms. Thus, the re-construction of a new and more convincing model is an urgent
necessity.
While there has been a major emphasis on the co-incidental changes in neurotransmitters and
the related receptors, neurogenesis and neurotrophic factors, less attention has been paid to
changes in glia. These non-neuronal cells, particularly astrocytes, were long considered to have
simple supportive role for neurons providing structure and adequate environmental condi‐
tions for neuronal functions. However, recent discoveries changed this view and led to a
reconceptualization of neuronal signaling with astrocytes forming an integral part of the
“tripartite synapse” along with the pre- and postsynaptic neurons [190]. In fact, glia was shown
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to use variations in cytoplasmic calcium as a form of cellular excitability allowing signaling to
other glia, neurons and blood vessels [191]. The astrocytes excitability can be triggered by
various neurotransmitters receptors expressed on glia and, in turn, these cells can release a
wide variety of gliotransmitters including glutamate, adenosine triphosphate and D-serine,
which regulate synaptic transmission and plasticity [191] [192]. Strikingly, reductions in the
density and ultrastructure of glial cells were detected in fronto-limbic regions in major
depression [193, 194], indicating the relevance of studying these cells in the pathophysiological
basis of MDD. Also, glial cells seem to play a central role in inflammation that contributes to
the main symptom of depression [195, 196], while fluoxetine requires microglia to exert its
neuroprotective action [184].
Being a heterogeneous condition, depression is unlikely to be explained by a single patho‐
physiological disturbance, hence, it is not expected that a single mechanism of drug action can
be uniformly effective. A new vision in which neurons and glial cells are involved side by side
will be more adequate to explain the heterogeneity of MDD. In the basis of very recent
researches, a “network hypothesis”, in which information processing implicating neurons and
glia within particular brain networks is altered in MDD and can be improved by AD treatment,
can be proposed. Hence, Sheline et al. [197] reported, in depressed subjects, a dramatic increase
in connectivity of three different brain networks: the cognitive control network, default mode
network and affective network, with the “dorsal nexus”, a bilateral region of the dorsal medial
PFC. Recent reports using subpsychomimetic doses of ketamine, an ionotropic glutamatergic
N-methyl-D-aspartate (NMDA) receptor antagonist, showed a rapid AD response in MDD
subjects [198], which is hypothesized to be mediated by i) lower Glx/glutamate ratio in the PFC
associated with reductions in glial cells in the same region [199] and, ii) decreased functional
connectivity of the default mode network to the dorsal nexus [200]. More investigations are
needed to define how brain networks can respond faster to this novel antidepressant, how
neurons and glia are implicating in such process and how the involved mechanism can be used
to the discovery of new treatment strategies in MDD.
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